Sat, Nov 22, 2014, 8:33 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

YM BioSciences, Inc. Ordinary S Message Board

  • rfj1862 rfj1862 Jan 30, 2006 7:42 PM Flag


    Hopefully today sucked up the remaining shares from our favorite seller.

    Just as a side note, when I spoke with the opinion leaders at ASCO GI, none had a clue about nimotuzumab. Both said they would "look into it."

    One of the OLs I spoke with stated that rash was correlated with response, which was what inspired me to speak with him. The second OL is involved in trials of panitumumab--he had no clue either.

    Interesting that experts in the field still have no clue, and it speaks to the fact that the potential of nimotuzumab (and YMI in general) is completely unknown.

    YMI needs to get off their butts and publish, publish, publish. Even though it hasn't been tested in CRC, an abstract at ASCO GI highlighting the lack of rash probably would have been accepted, given that Erbitux is so commonly used for CRC.


    SortNewest  |  Oldest  |  Most Replied Expand all replies

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Exa Corporation
NasdaqGMFri, Nov 21, 2014 3:59 PM EST
Celgene Corporation
NasdaqGSFri, Nov 21, 2014 4:00 PM EST